To assess the effects of rituximab on immunoglobulin levels and incidence of infection among patients on rituximab

Methods: Data was collected of all (N=105) patients who received Rituximab between May 2014 until April 2015 at the Haywood Hospital where patients attend for Rituximab injections.

Data was collected retrospectively from the Diamond System, Medisec system and Clinical Information System and entered onto an excel spread sheet which included following details

- Start date of Rituximab
- IgG levels prior to Rituximab and current IgG levels
- Total doses of rituximab and frequency of IgG monitoring
- Intermittent infections and type of infections.

Results: We observed that 82 out of 105 patients were started on rituximab after February 2011 when the BSR guidance was published and 53 out of 105 patients had their immunoglobulin levels checked prior to commencing rituximab

35/76 (46%) patients had 1 or more episodes of infections whilst on Rituximab which required treatment. Of these, 16 (46%) had recurrent infections.

39 patients had dropped their IgG levels after starting rituximab 18 (46%) of these suffered from infections.

17 patients had a drop in IgG $\geq 20\%$ and 6 of these (36%) had recurrent infections and 1 patient had 1 episode of infection.

None of the patients had dropped their IgG levels below 5

Conclusions: A significant number of patients (35/76 =46%) had 1 or more episodes of infections despite IgG levels being above lower normal limit

Among patients who dropped their IgG levels had increased number infections. Also they had more than 1 episodes of infection

Patients who dropped IgG levels $\geq 20\%$ suffered with recurrent infections

References:

- [1] BSR and BHPH guidelines on the use of rituximab in rheumatoid arthritis doi:10.1093/rheumatology/ker106b.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.1160

AB0400 EFFICACY AND SAFETY OF INTRAVENOUS AND SUBCUTANEOUS TOCILIZUMAB IN A COHORT OF PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS IN REAL-LIFE

G. Pomponio, C. Tontini, A. Angeletti, D. Olivari, D. Benfaremo, L. Manfredi, M.G. Danielli, P. Fraticelli, M.M. Luchetti, G. Moroncini, A. Gabrielli. *Department of Internal Medicine, Azienda Ospedaliero-universitaria 'Ospedali Riuniti', Ancona, Italy*

Background: Tocilizumab (TCZ) is a humanized monoclonal anti-interleukin-6 receptor antibody, used for the treatment of moderate to severe rheumatoid arthritis (RA). Although TCZ has been proved to be highly effective and safe in RA patients in large clinical trials, few data are available from real-life practice [1].

Objectives: To evaluate efficacy, safety and retention rate of intravenous (IV) and subcutaneous (SC) TCZ in a real-world setting.

Methods: We evaluated patients affected by moderate-to-severe RA and treated with TCZ from April 2010 to January 2017. Data of patients treated with IV-TCZ until January 2017 were collected retrospectively, while patients treated with either IV or SC-TCZ from January 2015 were included in a prospective cohort and assessed for disease activity, treatment discontinuation and/or onset of adverse events (AEs). DAS28-CRP, CDAI and SDAI scores were used for disease activity assessment and paired t test was used for statistical analysis. Treatment retention rate was estimated by Kaplan-Meier method.

Results: We evaluated 100 patients, 58 treated with IV-TCZ (8 mg/kg every 4w), 16 with SC-TCZ (162 mg every week), 26 switched from IV to SC during followup and 6 of these returned to IV-TCZ for cutaneous intolerance (80 females, median age 63 y, median duration of disease 11 y, median follow-up 16 months). Seventy-eight patients (78%) were treated with monotherapy and twenty-two (22%) in combination with methotrexate. At baseline, disease activity was severe in 87% of patients, moderate in 6% and mild or inactive in 7%; at the latest follow-up 60% of patients are in clinical remission. The mean DAS28-CRP in IV-TCZ and SW-TCZ groups considered as a whole was 4.34 at baseline and 2.71 at the latest follow-up available ($p < 0.0001$). In the SC-TCZ group, mean basal DAS28-CRP was 3.70 vs 1.89 measured at the latest follow-up ($p < 0.0001$). Fifty-three patients (53%) discontinued TCZ because of inefficacy (19), AEs (13) or other reasons (21, mostly lost to follow-up). Infections were the most frequent AE (45.1/100 person-years), 3 cases of severe pneumonia, one required treatment discontinuation. Infusion reactions were reported in 6/58 IV-TCZ patients, while injection site reactions in 14/42 SC-TCZ patients. Six of these intolerant patients were subsequently treated with i.v. tocilizumab without reactions. We observed an overall high retention rate of IV-TCZ and SW-TCZ (91.1%, 81.2%, 70.6%, 61.3%, 57.1% and 50% at 1, 2, 3, 4, 5, and 6 years respectively). The retention rate of SC-TCZ patients at 3 years was about 77%. The difference between IV/SW-TCZ and SC-TCZ groups was not significant (Fig. 2).

Conclusions: TCZ is effective, well tolerated and safe in a population of RA patients followed in a real-life setting.

No unexpected AE was observed in this large population followed for a long period. Interestingly retention rate was not affected by the administration route and in real life many patients can safely shift across different administration modalities.

References:

- [1] Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, et al. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. *Ann Rheum Dis*. 2015 Sep 15.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6724

AB0401 THE EFFICIENT REGULATION OF TOCILIZUMAB FOR THE EXPRESSION OF CD4+/CD8+ T/CD19 + B CELLS AND THE IMMUNOGLOBULIN IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

H. Li¹, H. Zeng². ¹Department of Pediatric Allergy, Immunology and Rheumatology; ²Department of Pediatric Allergy, Immunology and Rheumatology, Guangzhou Women and Children's Medical Center, Guangzhou, China

Objectives: To study the influence of tocilizumab on lymphocyte subsets, immunoglobulin and biochemical indicators of Systemic juvenile idiopathic arthritis.

Methods: DMARDs poor efficacy in children with severe SJA 18 patients were divided into two groups, of which eight patients tocilizumab + DMARDs group (including a case of refractory MAS), 10 patients in the placebo + DMARDs control group, according to the weight $> 30\text{kg}$, 8mg/kg, $< 30\text{kg}$, 12mg/kg, injected once every two weeks in hospital. Symptoms and CD3 +, CD4 +, CD8 + T, CD19 + B, CD16 + 56-NK cell ratio in two groups were observed by the flow cytometry before or after 12 weeks treatment. Comparing immunoglobulin IgG, IgM, IgA, IgE with baseline after the therapy in two group, and continuous observe inflammatory markers (CRP, ESR, FER, WBC) and ALT/AST changes, adverse reactions and reduce stopping hormone case inductive analysis in following 12 weeks.

Results: After 12 weeks, tocilizumab + DMARDs group, CRP, ESR, FER were significantly decreased, the most frequently occurring adverse reaction was infection, mostly upper respiratory tract infection, followed by elevated transaminase, cholesterol, low-density lipoprotein High-density lipoprotein and triglyceride levels increased; two groups no serious adverse events (three-line reduction, severe infections, etc.). the proportion of CD4 + T, CD19 + B cells in Tocilizumab group were lower than baseline ($P < 0.05$), CD8, CD3 + T cells were increased in comparing with baseline, however, no significant change with CD16 + 56-NK cells ($P > 0.05$), and immunoglobulins IgG, IgM, IgA lower than baseline ($P < 0.05$). The control group had no significant difference ($P > 0.05$).

Conclusions: Tocilizumab can significantly reduce inflammatory markers (CRP, ESR, FER), but affect lipid metabolism and ALT/AST. Blocking IL-6 can be adjusted hyperthyroidism humoral and regulate CD4 + T, CD19 + B cells, reduce joint destruction. Tocilizumab can effectively control the development of DMARDs poor efficacy SJA.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2114

AB0402 RITUXIMAB MAY DELAY THE MOVEMENT OF RHEUMATOID ARTHRITIS PATIENTS ON CARDIORENAL CONTINUUM: RESULTS FROM A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY

I.R. Gaisin¹, L.V. Ivanova², A.A. Trukchina², A.A. Tukmacheva², Y.A. Volkova¹, A.A. Tebenkova¹, N.I. Maximov¹. ¹Izhevsk State Medical Academy; ²Clinical Diagnostic Centre of the Udmurt Republic, Izhevsk, Russian Federation

Background: Similarities in risk factors, initial stages, progression and final stage of both atherosclerotic cardiovascular disease (CVD) and chronic kidney disease (CKD) allowed formulating a concept of cardiorenal continuum.¹ CVD and CKD remain the main causes of mortality in rheumatoid arthritis (RA) patients.^{2,3}

Objectives: We aimed to evaluate the effects of rituximab biologic therapy on cardiorenal continuum of RA patients.

Methods: Biologics-naïve RA patients (n=50; age 55.1 $\pm$ 10.3) were followed up for 72 months after commencing and continuing rituximab therapy (1–10 standard courses) compared with 30 control RA patients (age 53.2 $\pm$ 9.8).

Results: At year 6, rituximab patients have fewer incidences of hypertension, anxiety/depression, atherosclerosis and diastolic dysfunction than control patients (Table).

There were no significant differences in frequencies of other risk factors, signs of asymptomatic multiorgan damage and cases of established heart, cerebrovascular and renal diseases/complications.

Conclusions: Rituximab may be effective in delay of the movement of RA patients on cardiorenal continuum. The clinical implications of rituximab for cardiorenal correlations in RA patients need to be confirmed in large-scale clinical outcome trials.

References:

- [1] Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. *Am J Kidney Dis* 2000;35(4, Suppl. 1):117–31.
[2] Avina-Zubieta JA, Choi HK, Sadatsafar M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum* 2008;59:1690–7.
[3] Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2011;25:469–83.